New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Learn More
Last Close
Sep 16  •  04:00PM ET
0.1830
Dollar change
-0.0077
Percentage change
-4.04
%
Index- P/E- EPS (ttm)-0.47 Insider Own35.23% Shs Outstand162.39M Perf Week-17.68%
Market Cap42.26M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float149.57M Perf Month-23.46%
Enterprise Value47.66M PEG- EPS next Q- Inst Own6.25% Short Float0.74% Perf Quarter-47.08%
Income-74.78M P/S- EPS this Y- Inst Trans-34.26% Short Ratio0.82 Perf Half Y-76.17%
Sales0.00M P/B0.34 EPS next Y- ROA-50.56% Short Interest1.11M Perf YTD-78.10%
Book/sh0.54 P/C25.93 EPS next 5Y- ROE-67.13% 52W High2.10 -91.29% Perf Year-70.52%
Cash/sh0.01 P/FCF- EPS past 3/5Y-16.97% -13.58% ROIC-84.13% 52W Low0.18 0.38% Perf 3Y-91.12%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility10.69% 9.95% Perf 5Y-95.38%
Dividend TTM- EV/Sales- EPS Y/Y TTM58.00% Oper. Margin- ATR (14)0.02 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.13 Sales Y/Y TTM- Profit Margin- RSI (14)34.51 Recom-
Dividend Gr. 3/5Y- - Current Ratio0.13 EPS Q/Q100.22% SMA20-16.86% Beta0.45 Target Price-
Payout- Debt/Eq0.08 Sales Q/Q- SMA50-28.22% Rel Volume2.06 Prev Close0.19
Employees25 LT Debt/Eq0.01 Earnings- SMA200-68.01% Avg Volume1.35M Price0.18
IPOFeb 02, 2015 Option/ShortYes / Yes EPS/Sales Surpr.- - Trades Volume2,767,595 Change-4.04%
Sep-11-25 07:00AM
Sep-09-25 08:47AM
Sep-08-25 08:50AM
Sep-04-25 10:05AM
Aug-27-25 09:45AM
10:45AM Loading…
Aug-08-25 10:45AM
Jul-29-25 03:01PM
Jul-28-25 10:38AM
Jul-17-25 09:15AM
Jul-09-25 08:00AM
Jun-30-25 09:21AM
Jun-10-25 11:13AM
Jun-03-25 09:15AM
May-23-25 09:17AM
May-22-25 09:41PM
03:12PM Loading…
03:12PM
11:05AM
May-14-25 09:15AM
May-13-25 09:15AM
Apr-22-25 09:20AM
Apr-09-25 09:25AM
Apr-05-25 12:10PM
Apr-04-25 09:40AM
Mar-03-25 09:15AM
09:00AM
Feb-26-25 01:25PM
09:15AM
Feb-19-25 10:10AM
Jan-07-25 09:15AM
09:15AM
09:15AM Loading…
Jan-06-25 09:15AM
09:10AM
Dec-30-24 09:00AM
Dec-23-24 09:00AM
Dec-20-24 03:40PM
09:00AM
Nov-04-24 08:31AM
Oct-17-24 09:15AM
Oct-16-24 09:28AM
Sep-19-24 09:00AM
Sep-17-24 09:00AM
Sep-13-24 09:00AM
Sep-11-24 09:15AM
Jul-26-24 07:36AM
05:30AM
Jun-14-24 09:06AM
May-24-24 09:20AM
08:45AM
May-16-24 08:53AM
Apr-30-24 11:00AM
Apr-24-24 09:00AM
Apr-18-24 08:45AM
Mar-04-24 09:00PM
Feb-15-24 09:25AM
Feb-14-24 10:01AM
Feb-13-24 09:46AM
09:31AM
Jan-25-24 12:45PM
Jan-18-24 09:30AM
Jan-16-24 08:00AM
Nov-28-23 08:30AM
Nov-23-23 09:30AM
Nov-22-23 10:44AM
Nov-21-23 08:30AM
Nov-14-23 09:00AM
Nov-10-23 08:30AM
Nov-07-23 08:30AM
Oct-24-23 09:00AM
Oct-11-23 09:25AM
08:30AM
Oct-10-23 08:00AM
Oct-04-23 09:00AM
Oct-02-23 12:05PM
09:25AM
08:30AM
Sep-29-23 09:15AM
09:15AM
Sep-21-23 03:00PM
Sep-19-23 08:30AM
Sep-06-23 12:40AM
Aug-30-23 09:15AM
Aug-21-23 09:15AM
Aug-10-23 12:06AM
Aug-09-23 09:00AM
Jul-17-23 07:29AM
Jun-23-23 05:00PM
Jun-08-23 08:45AM
Apr-03-23 09:00AM
Mar-29-23 09:00AM
Mar-13-23 08:30AM
Feb-23-23 04:04PM
Nov-30-22 05:20PM
Oct-26-22 12:01AM
Oct-24-22 08:11PM
08:00AM
Oct-21-22 05:00PM
Oct-17-22 08:30AM
Sep-01-22 08:08AM
Jul-25-22 10:15AM
Jul-01-22 08:37PM
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.